Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of BioNTech SE ADR (NASDAQ: BNTX) closed at $103.56 in the last session, down -7.10% from day before closing price of $111.48. In other words, the price has decreased by -$7.10 from its previous closing price. On the day, 1.67 million shares were traded. BNTX stock price reached its highest trading level at $115.93 during the session, while it also had its lowest trading level at $102.19.
Ratios:
We take a closer look at BNTX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.79. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on November 08, 2024, Upgraded its rating to Buy and sets its target price to $137 from $90 previously.
On September 24, 2024, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also upped its target price recommendation from $93 to $145.
Jefferies Upgraded its Hold to Buy on September 17, 2024, whereas the target price for the stock was revised from $96 to $150.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Tureci Ozlem bought 556,000 shares for $108.73 per share.
ATHOS KG bought 8,036 shares of BNTX for $946,154 on Oct 16 ’24. On Oct 14 ’24, another insider, ATHOS KG, who serves as the 10% Owner of the company, bought 25,424 shares for $120.83 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 24827473920 and an Enterprise Value of 8361848832. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.52 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 2.751 whereas that against EBITDA is -30.462.
Stock Price History:
Over the past 52 weeks, BNTX has reached a high of $131.49, while it has fallen to a 52-week low of $76.53. The 50-Day Moving Average of the stock is -8.63%, while the 200-Day Moving Average is calculated to be 8.41%.
Shares Statistics:
According to the various share statistics, BNTX traded on average about 1.01M shares per day over the past 3-months and 921340 shares per day over the past 10 days. A total of 239.74M shares are outstanding, with a floating share count of 239.12M. Insiders hold about 0.26% of the company’s shares, while institutions hold 20.41% stake in the company. Shares short for BNTX as of 1730332800 were 2017748 with a Short Ratio of 2.01, compared to 1727654400 on 1859038. Therefore, it implies a Short% of Shares Outstanding of 2017748 and a Short% of Float of 4.04.
Earnings Estimates
The current market rating for BioNTech SE ADR (BNTX) reflects the collective analysis of 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.96, with high estimates of -$1.23 and low estimates of -$3.03.
Analysts are recommending an EPS of between -$1.42 and -$4.99 for the fiscal current year, implying an average EPS of -$3.02. EPS for the following year is -$3.38, with 18.0 analysts recommending between -$0.06 and -$7.52.
Revenue Estimates
According to 11 analysts, the current quarter’s revenue is expected to be $1.15B. It ranges from a high estimate of $1.75B to a low estimate of $853.66M. As of the current estimate, BioNTech SE ADR’s year-ago sales were $1.48BFor the next quarter, 11 analysts are estimating revenue of $217.65M. There is a high estimate of $310.9M for the next quarter, whereas the lowest estimate is $145M.
A total of 17 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $2.77B, while the lowest revenue estimate was $2.4B, resulting in an average revenue estimate of $2.6B. In the same quarter a year ago, actual revenue was $3.82BBased on 19 analysts’ estimates, the company’s revenue will be $2.6B in the next fiscal year. The high estimate is $3.46B and the low estimate is $1.81B.
